Repurposing inhibitors may provide new treatment approach for ovarian cancer

(The Wistar Institute) Wistar researchers have found rationale for repurposing a class of antitumor compounds called HDAC inhibitors as a new therapeutic option for ovarian cancer with mutations in the ARID1A gene.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news